E-resources
Peer reviewed
Open access
-
Sapena, Victor; Enea, Marco; Torres, Ferran; Celsa, Ciro; Rios, Jose; Rizzo, Giacomo Emanuele Maria; Nahon, Pierre; Mariño, Zoe; Tateishi, Ryosuke; Minami, Tatsuya; Sangiovanni, Angelo; Forns, Xavier; Toyoda, Hidenori; Brillanti, Stefano; Conti, Fabio; Degasperi, Elisabetta; Yu, Ming-Lung; Tsai, Pei-Chien; Jean, Kevin; El Kassas, Mohamed; Shousha, Hend Ibrahim; Omar, Ashraf; Zavaglia, Claudio; Nagata, Hiroko; Nakagawa, Mina; Asahina, Yasuhiro; Singal, Amit G; Murphy, Caitlin; Kohla, Mohamed; Masetti, Chiara; Dufour, Jean-François; Merchante, Nicolas; Cavalletto, Luisa; Chemello, Liliana Lc; Pol, Stanislas; Crespo, Javier; Calleja, Jose Luis; Villani, Rosanna; Serviddio, Gaetano; Zanetto, Alberto; Shalaby, Sarah; Russo, Francesco Paolo; Bielen, Rob; Trevisani, Franco; Cammà, Calogero; Bruix, Jordi; Cabibbo, Giuseppe; Reig, Maria
Gut, 03/2022, Volume: 71, Issue: 3Journal Article
The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration. We pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson. Recurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I =74.6%) and 5.7 (2.5 to 15.3, I =54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p<0.001), performance status (2 vs 0, RR=4.35, 95% CI 1.54 to 11.11; 2 vs 1, RR=3.7, 95% CI 1.3 to 11.11; p=0.01) and tumour burden pre-HCC treatment (multifocal vs solitary nodule, RR=1.75, 95% CI 1.25 to 2.43; p<0.001). No significant difference was observed in RR between the DAA-exposed and DAA-unexposed groups in propensity score-matched patients (RR=0.64, 95% CI 0.37 to 1.1; p=0.1). Effects of DAA exposure on HCC recurrence risk remain inconclusive. Active clinical and radiological follow-up of patients with HCC after HCV eradication with DAA is justified.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.